184 related articles for article (PubMed ID: 31642045)
1. Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE).
Fleischmann R; Weinblatt M; Ahmad H; Maldonado MA; Alemao E; Ye J; Schiff M
Rheumatol Ther; 2019 Dec; 6(4):559-571. PubMed ID: 31642045
[TBL] [Abstract][Full Text] [Related]
2. Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada.
Foo J; Morel C; Bergman M; Baerwald C; Rodriguez-Heredia JM; Marshall A; Polanco-Sánchez C; Postema R
Rheumatol Int; 2019 Sep; 39(9):1621-1630. PubMed ID: 31240388
[TBL] [Abstract][Full Text] [Related]
3. Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis.
Degboé Y; Schiff M; Weinblatt M; Fleischmann R; Ahmad HA; Constantin A
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32604962
[TBL] [Abstract][Full Text] [Related]
4. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.
Sokolove J; Schiff M; Fleischmann R; Weinblatt ME; Connolly SE; Johnsen A; Zhu J; Maldonado MA; Patel S; Robinson WH
Ann Rheum Dis; 2016 Apr; 75(4):709-14. PubMed ID: 26359449
[TBL] [Abstract][Full Text] [Related]
5. A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity.
Park SH; Han X; Lobo F; Nanji S; Patel D
Clinicoecon Outcomes Res; 2020; 12():589-594. PubMed ID: 33116698
[TBL] [Abstract][Full Text] [Related]
6. HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.
Rigby W; Buckner JH; Louis Bridges S; Nys M; Gao S; Polinsky M; Ray N; Bykerk V
Arthritis Res Ther; 2021 Sep; 23(1):245. PubMed ID: 34537057
[TBL] [Abstract][Full Text] [Related]
7. Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.
Jabado O; Maldonado MA; Schiff M; Weinblatt ME; Fleischmann R; Robinson WH; He A; Patel V; Greenfield A; Saini J; Galbraith D; Connolly SE
Rheumatol Ther; 2022 Apr; 9(2):391-409. PubMed ID: 34878629
[TBL] [Abstract][Full Text] [Related]
8. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM
Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953
[TBL] [Abstract][Full Text] [Related]
9. Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study.
Jansen DTSL; Emery P; Smolen JS; Westhovens R; Le Bars M; Connolly SE; Ye J; Toes REM; Huizinga TWJ
RMD Open; 2018; 4(1):e000564. PubMed ID: 29657830
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.
Harrold LR; Litman HJ; Connolly SE; Alemao E; Kelly S; Rebello S; Hua W; Kremer JM
Rheumatol Ther; 2019 Jun; 6(2):217-230. PubMed ID: 30868550
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
Alten R; Tony HP; Bannert B; Nüßlein H; Rauch C; Connolly SE; Chartier M; Lozenski K; Hackl R; Forster A; Peichl P
Clin Rheumatol; 2023 Sep; 42(9):2321-2334. PubMed ID: 37314665
[TBL] [Abstract][Full Text] [Related]
12. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
Keystone EC; Ahmad HA; Yazici Y; Bergman MJ
Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab.
Fleischmann R; Connolly SE; Maldonado MA; Schiff M
Arthritis Rheumatol; 2016 Sep; 68(9):2083-9. PubMed ID: 27111089
[TBL] [Abstract][Full Text] [Related]
14. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J
Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
[TBL] [Abstract][Full Text] [Related]
15. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.
Schiff M; Weinblatt ME; Valente R; van der Heijde D; Citera G; Elegbe A; Maldonado M; Fleischmann R
Ann Rheum Dis; 2014 Jan; 73(1):86-94. PubMed ID: 23962455
[TBL] [Abstract][Full Text] [Related]
17. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
Weinblatt ME; Schiff M; Valente R; van der Heijde D; Citera G; Zhao C; Maldonado M; Fleischmann R
Arthritis Rheum; 2013 Jan; 65(1):28-38. PubMed ID: 23169319
[TBL] [Abstract][Full Text] [Related]
19. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
20. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
